Onco Wiki / Biomarcador

Estado del EBV (EBER-ISH en el tejido tumoral)

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDBIO-EBV-STATUS
TipoBiomarcador
Aliaces
EBEREBVSituación del EBVEBV статус (EBER-ISH на тканині)Virus Epstein-Barr
Situaciónreviewed 2026-04-25 | pending_clinical_signoff
EnfermedadesDIS-AITL DIS-GASTRIC
FuentesSRC-NCCN-BCELL-2025

Datos sobre biomarcadores

Tipo de biomarcadorviral_load
Medición
MétodoEBER (EBV-encoded RNA) in-situ hybridization on FFPE tissue. Serum EBV-DNA quantitative for systemic involvement
Unidadescategorical (positive | negative); EBV-DNA copies/mL for serum
Productos químicos y químicosNinguna declarada

Notas

Cross-disease etiologic + therapeutic significance: - **Endemic Burkitt** (equatorial Africa): EBV+ in ~95% - **Sporadic Burkitt** (Western): EBV+ in ~15% - **Classical Hodgkin**: EBV+ in ~30-40% (mixed cellularity highest) - **Post-transplant LPD (PTLD)**: EBV-driven; rituximab + reduce immunosuppression often curative - **HIV-associated DLBCL / plasmablastic / primary effusion**: EBV+ common - **NK/T nasal-type lymphoma**: EBV+ universally - **AITL microenvironment**: EBV+ B-cells frequent - **EBV+ DLBCL of elderly** (WHO 5th-ed entity): defined by EBV+ Drives different treatment context: - PTLD → reduce immunosuppression + rituximab - HIV-associated → cART + standard regimen - EBV+ HL has same regimen but PD-1 blockade emerging response differential Currently informational in our KB; not algorithm-driving for treatment selection but documented for clinical context.

Utilizado por

Relevancia terapéutica

Biomarcador

Señal de alerta